Ketamine for depression: all studies (page 32)

Hope for Neurotic Disorders: A Summary of New Zealand Research on the Development of Biomarkers and Novel Treatments.

Journal of the Royal Society of New Zealand February 1, 2026 Neil McNaughton, Shabah M. Shadli, Ben Beaglehole et al.

The neurotic disorders (e.g., depression, dysthymia, generalized anxiety disorder, panic disorder, agoraphobia, social anxiety, post-traumatic stress disorder, and obsessive-compulsive disorder) are costly and difficult to treat. Diagnosis is based on symptoms not biological causes. Here, we summarize New Zealand-based work developing EEG biomarkers and novel treatments. Working at the...

DOI: 10.1002/snz2.70002 Full text Depression Ketamine EEG Anxiety biomarker +1

The Emerging Crisis in Non-Prescribed Ketamine Use: A Rapid Attenuation of Depression in Face of Abuse and "Chill-out" or Escapism Drug.

Substance Use & Misuse February 1, 2026 Kai-Uwe Lewandrowski, Kenneth Blum, Sergio Schmidt et al.

Since 2000, rates of suicide and opioid overdose have sharply increased. Approximately one-third of individuals with major depressive disorder (MDD) experience treatment-resistant depression (TRD), highlighting the urgent need for novel therapeutic approaches. This review synthesizes pivotal preclinical and clinical findings on low-dose ketamine's rapid antidepressant effects and examines...

DOI: 10.1080/10826084.2025.2612330 Full text Ketamine Dopamine Rapid antidepressant effect

Placebo Effects in the Treatment of Depression-Implications for the Psychedelic Renaissance.

Neurologic Clinics February 1, 2026 Mina Ansari, Sophie I Elliott, Sophie E Holmes et al. 1 citation

The development of novel, rapid-acting treatments and the resurgence of interest in the therapeutic potential of psychedelic-like compounds has stimulated excitement and enthusiasm within the pharmaceutical industry, and provided new hope for millions of individuals suffering with mental illness such as major depressive disorder and post-traumatic stress disorder. This review summarizes the...

DOI: 10.1016/j.ncl.2025.08.009 Full text Ketamine MDMA Psilocybin Psychedelic therapy +6

Multimodal rapid anti-depression: Esketamine combined with dexmedetomidine patient-controlled sleep for treatment-resistant depression - A retrospective study.

Journal of Affective Disorders January 30, 2026 Yao-Zu Li, Cai-Qun Zhao, Mu-Yan Zuo et al.

To evaluate the efficacy and safety of a multimodal rapid anti-depression therapy that combines esketamine treatment with dexmedetomidine patient-controlled sleep (PCSL) in patients with treatment-resistant depression (TRD). We retrospectively included 233 patients with TRD who received the multimodal treatment. Baseline clinical characteristics were collected. Follow-up assessments were...

DOI: 10.1016/j.jad.2026.121311 Full text Esketamine Treatment-resistant depression Dexmedetomidine Multimodal rapid anti-depression +1

Prophylactic esketamine to reduce postpartum depression in primiparae: A multicentre, double-blind, randomised clinical trial.

European journal of anaesthesiology January 29, 2026 Tiantian Chu, Xiaoling Peng, Keliang Wan et al. 2 citations

Postpartum depression (PPD) is a common complication after childbirth, especially in primiparae. This trial sought to evaluate whether prophylactic administration of esketamine during the perinatal period could prevent PPD in primiparae without predisposition to prenatal depression. A prospective, double-blind, multicentre, randomised controlled trial. Three academic hospitals. Primiparae...

DOI: 10.1097/EJA.0000000000002348 Full text

Combining Intranasal Esketamine and Electroconvulsive Therapy in Severe Treatment‑Resistant Depression: A Case Series.

The Journal of ECT January 29, 2026 Sergi López-rodríguez, Aida De Arriba-Arnau, José Manuel Menchón et al. 1 citation

This case series describes the combined use of electroconvulsive therapy (ECT) and intranasal esketamine (ESK)-2 rapidly acting, evidence-based options for treatment-resistant depression (TRD). Each can leave residual symptoms or early relapse. Whether concurrent use confers more durable benefit remains unclear. We followed 4 adults (50 to 72 y) with severe TRD who had shown partial or waning...

DOI: 10.1097/yct.0000000000001233 Full text Esketamine Treatment-resistant depression Case series Combination therapy +2

Ketamine in the treatment of bipolar depression

Brazilian Journal of Health Review January 28, 2026 Juliana Chies Galvan, Marina Chies Galvan, Rafael Moreno Ferro de Araújo

Bipolar depression is the most prevalent state throughout the life of the bipolar patient, even so, few studies have focused on the treatment of depression in this population. Between the available medications approved for treatment of bipolar depression, ketamine is an option that must be considered. The purpose of this paper was to review the scientific evidence on the efficacy of using...

DOI: 10.34119/bjhrv9n1-120

Modulating tonic NMDA receptor currents: mechanistic insights into ketamine, esketamine, and dextromethorphan for major depressive disorder and implications for the discovery and development of investigational agents.

Expert Opinion on Therapeutic Targets January 28, 2026 Gia Han Le, Roger S McIntyre 1 citation

Up to 50% of adults with major depressive disorder (MDD) fail to achieve remission after two or more monoaminergic antidepressants and meet criteria for treatment-resistant depression (TRD). Low-dose intravenous ketamine, intranasal esketamine, and oral dextromethorphan represent the first glutamatergic treatments to exhibit rapid and robust efficacy in persons with TRD, yet their precise...

DOI: 10.1080/14728222.2026.2619757 Full text Treatment-resistant depression Esketamine Nmda receptor subunits Antidepressant mechanisms +2

Systematic review and meta-analysis of intranasal esketamine for treatment-resistant depression: Evidence from real-world studies.

Journal of Affective Disorders January 28, 2026 Clara De Oliveira Lapa, Thiago Viola, Rodrigo Delfino et al. 3 citations

Intranasal esketamine has demonstrated efficacy and safety for treatment-resistant depression in randomized controlled trials, however the generalizability of these findings to clinical practice remains unclear. This systematic review and meta-analysis aimed to synthesize real-world evidence of intranasal esketamine in patients with treatment-resistant depression. A systematic search was...

DOI: 10.1016/j.jad.2026.121257 Full text Esketamine Treatment-resistant depression Intranasal Meta-analysis +2

PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION

International Journal of Innovative Technologies in Social Science January 28, 2026 Łukasz Deska, Cezary Kosmecki, Dawid Głaz et al.

This manuscript comprehensively reviews psilocybin-assisted therapy for major depressive disorder and treatment-resistant depression. It aims to synthesize current understanding regarding its mechanisms, efficacy, safety, costs, and accessibility, comparing it with conventional antidepressant and ketamine treatments. The methodology involved a narrative synthesis of academic literature, drawing...

DOI: 10.31435/ijitss.1(49).2026.4711 Psilocybin Major depressive disorder Treatment-resistant depression Ketamine +9